Navigation Links
Can Implantable Devices for Heart Failure Help Assess Risk of Future Adverse Events for Heart Failure Patients?
Date:9/24/2008

ICDs monitoring intrathoracic fluid identify patients at a high risk for

subsequent adverse events in heart failure patients

TORONTO, Sept. 24 /PRNewswire/ -- Today a clinical trial "PARTNERS HF: Multi-Site Program to Access and Review Trending Information and Evaluate Correlation to Symptoms in Patients with Heart Failure," was presented at the 12th Annual Scientific Meeting of the Heart Failure Society of America (HFSA) by Dr. David Whellan, who is an Associate Professor of Medicine, Jefferson Heart Institute, Thomas Jefferson University, Philadelphia, PA. This clinical trial highlighted the results of evaluating the intrathoracic fluid data collected by implantable devices used to treat patients with heart failure as a possible tool to determine subsequent heart failure related adverse events. The scientific meeting began Monday at the Metro Toronto Convention Center in Toronto, Ontario, Canada, and also featured new research, advances in treatment, guidelines for care, debates, and late breaking clinical trials.

"This finding could be important to help us better understand how body functions (i.e., excess fluid) effect the progression of heart failure," said Dr. Barry Greenberg, HFSA President, and Professor of Medicine, and Director, Advanced Heart Failure Treatment Program, University of California, San Diego. "Diagnostic measures that would lead to early detection of changes in various parameters could ultimately allow us to intervene at an early time and thus prevent cardiac events from occurring."

This trial enrolled 1,000 patients and followed them for a period of 12 months in order to determine the outcome of diagnostic information obtained from an implantable cardiac defibrillator which measures changes in fluid levels in the thoracic cavity. Low electrical pulses travel across the thorax to measure the level of resistance, changes indicate increasing or decreasing fluid levels. Worsening heart failure is commonly characterized by fluid accumulation. This study examined whether certain changes in the fluid index could identify patients at risk for subsequent heart failure event. Additionally, if a potentially life-threatening arrhythmia is detected, the devices in this study were capable of delivering an electrical pulse or shock to correct it.

Dr. Whellan explained that the trial observed how well the diagnostic parameters predicted the incidence of clinical events. "We now have this continuous diagnostic data available for patients during in-clinic visits as well as a remote follow up over the internet. This trial found that patients with a high intrathoric fluid were about three times more likely to have a subsequent heart failure event, independent of other clinical variables."

For a complete list of annual meeting sessions or for details on attending the conference, call (617) 226-7198 or visit http://www.hfsa.org and click on Annual Scientific Meeting. There is no registration fee for accredited journalists. Interview areas will be available on-site in addition to a fully-staffed press room with phone and internet accessibility.

About Heart Failure

Heart failure is a progressive condition in which the heart muscle becomes weakened after it is injured from heart attack or high blood pressure and gradually loses its ability to pump enough blood to supply the body's needs. Many people are not aware they have heart failure because the symptoms are often mistaken for signs of getting older. Heart failure affects from 4.6 to 4.8 million individuals in the United States. Demographic and clinical evidence strongly suggest the prevalence of heart failure will increase throughout the next decade. Ten to 15 years ago heart failure was considered a "death sentence;" however, recent advances in treatment have shown that early diagnosis and proper care in early stages of the condition are key to slowing, stopping or in some cases reversing progression, improving quality of life, and extending life expectancy. For more information on heart failure, please visit http://www.abouthf.org .

About the Heart Failure Society of America

The Heart Failure Society of America (HFSA) is a nonprofit educational organization, founded in 1994 as the first organized association of heart failure experts. Today HFSA has over 1,700 members and provides a forum for all those interested in heart function, heart failure research and patient care. The Society also serves as a resource for governmental agencies (FDA, NIH, NHLBI, CMS). The HFSA Annual Scientific Meeting is designed to highlight recent advances in the development of strategies to address the complex epidemiological, clinical and therapeutic issues of heart failure. Additional information on HFSA can be found at http://www.hfsa.org .


'/>"/>
SOURCE The Heart Failure Society of America
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. New Implantable Lenses Can Reduce the Need for Glasses After Cataract Surgery
2. U. of Md. Researchers to Develop Devices to Revolutionize Drug Research
3. Boston Scientific Announces CE Mark Approval for New Devices to Treat Heart Failure and Sudden Cardiac Death
4. New Research for Mechanical Support Devices in Pediatrics to Be Released at International Heart and Lung Transplant Meeting
5. Tepha Announces First Human Usage of Medical Devices Derived from New Class of Resorbable Polymers
6. Many Heart Attack Patients Dont Get Best Emergency Treatment
7. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
8. American Heart Association Comment Saving Lives in Type 2 Diabetics: Could It Be as Easy as Lowering Blood Pressure?
9. Terumo Heart to Announce Results of European Clinical Trial of DuraHeart(TM) LVAS at European Association of Cardiothoracic Surgeons Meeting in September
10. WorldHeart Announces Further Milestone in Miniaturized Assist Pump Development
11. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... , Oct. 2, 2017 Halo Labs announces the ... analysis system called the HORIZON at MIBio 2017 in ... subvisible and visible particulate matter in biopharmaceutical samples with unprecedented speed ... of the novel technique Backgrounded Membrane Imaging. ... The HORIZON subvisible particle analysis system ...
(Date:9/27/2017)... -- Commended for their devotion to personalized service, SMP Pharmacy Solutions ... in the South Florida Business Journal,s 50 Fastest-Growing Companies, and ... the national specialty pharmacy has found its niche.  To that ... be honored by SFBJ as the 2017 Power Leader in ... receive his award in October, Bardisa said of the three ...
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, Inc. ... response letter from the U.S. Food and Drug Administration ... of sirukumab for the treatment of moderately to severely ... additional clinical data are needed to further evaluate the ... severely active RA. ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Apple Rehab Shelton Lakes , which ... evacuation of the facility as part of a disaster drill on October 3rd. , ... and Shelton City Emergency Manager, as well as the Connecticut Long Term Care ...
(Date:10/13/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has released ... understood books in the Holy Scriptures, Revelation. The Book of Revelation paints a picture ... Many have tossed it off as mere rubbish, but Yisrayl Hawkins says that is ...
(Date:10/12/2017)... ... October 12, 2017 , ... First ... compliance program management, will showcase a range of technology and learning solutions at ... (NCAL) Convention and Expo to be held October 14–18, 2017 at the Mandalay ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics (ACMI) will ... during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual ... F. Collen, a pioneer in the field of medical informatics, this prestigious award is ...
(Date:10/12/2017)... ... 2017 , ... Leading pediatric oncology experts at Children’s National Health System ... Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by ... and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief of ...
Breaking Medicine News(10 mins):